# A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Bone and Soft Tissue Tumors

> **NCT06171282** · EARLY_PHASE1 · RECRUITING · sponsor: **Shanghai Yunying Medical Technology** · enrollment: 9 (estimated)

## Conditions studied

- Osteosarcoma
- Sarcoma
- Soft Tissue Sarcoma
- Bone Tumor

## Interventions

- **DRUG:** Recombinant oncolytic herpes simplex virus type Ⅰ (R130)

## Key facts

- **NCT ID:** NCT06171282
- **Lead sponsor:** Shanghai Yunying Medical Technology
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-12
- **Primary completion:** 2025-07-12
- **Final completion:** 2026-07-12
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2023-12-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06171282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06171282, "A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Bone and Soft Tissue Tumors". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT06171282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*